רוטה טק (חיסון חי פומי חמש ערכי נגד נגיף הרוטה)

Country: Iżrael

Lingwa: Ebrajk

Sors: Ministry of Health

Ingredjent attiv:

ROTAVIRUS G1 REASSORTANT; ROTAVIRUS G2 REASSORTANT; ROTAVIRUS G3 REASSORTANT; ROTAVIRUS G4 REASSORTANT; ROTAVIRUS P1A[8] REASSORTANT

Disponibbli minn:

MERCK SHARP & DOHME (ISRAEL - 1996) COMPANY LTD, ISRAEL

Kodiċi ATC:

J07BH

Għamla farmaċewtika:

SUSPENSION

Kompożizzjoni:

ROTAVIRUS P1A[8] REASSORTANT 2.3 X10 ^6 IU/DOSE; ROTAVIRUS G2 REASSORTANT 2.8 X10 ^6 IU/DOSE; ROTAVIRUS G4 REASSORTANT 2.0 X10^ 6 IU/DOSE; ROTAVIRUS G3 REASSORTANT 2.2 X10 ^6 IU/DOSE; ROTAVIRUS G1 REASSORTANT 2.2 X10 ^6 IU/DOSE

Rotta amministrattiva:

פומי

Tip ta 'preskrizzjoni:

מרשם נדרש

Manifatturat minn:

MERCK SHARP & DOHME CORP., USA

Grupp terapewtiku:

ROTA VIRUS DIARRHEA VACCINES

Indikazzjonijiet terapewtiċi:

RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes G1, G2, G3, and G4 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RoraTeq should be administered betwen 6 and 12 weeks of age.

Data ta 'l-awtorizzazzjoni:

2022-05-31